PCM
MCRB icon

Portolan Capital Management’s Seres Therapeutics MCRB Stock Holding History

Portolan Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,553
Closed -$1.1M – 132
2016
Q4 		$1.1M Sell
5,553
-8,795
-61% -$1.92M 0.15% 112
2016
Q3 		$3.53M Buy
14,348
+7,654
+114% +$2.69M 0.48% 68
2016
Q2 		$3.89M Buy
6,694
+730
+12% +$428K 0.56% 68
2016
Q1 		$3.17M Buy
+5,964
New +$3.11M 0.42% 82

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Portolan Capital Management's MCRB Position: Q1 2017 in Review

Portolan Capital Management sold out of Seres Therapeutics (MCRB) in Q1 2017, closing a stake of 5,553 shares — an estimated $1.1M sold.

Portolan Capital Management first reported a position in MCRB in Q1 2016 and held it in 4 quarters. The position peaked at $3.89M in Q2 2016. 79 funds tracked by Wall St. Rank hold MCRB as of Q1 2017.

  • Portolan Capital Management reported no remaining Seres Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Portolan Capital Management sold 5,553 Seres Therapeutics shares in Q1 2017, an estimated $1.1M.
  • Portolan Capital Management first reported a position in Seres Therapeutics in Q1 2016 and held it in 4 quarters.
  • Portolan Capital Management's Seres Therapeutics position peaked at $3.89M in Q2 2016.
  • 79 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2017.

Based on Portolan Capital Management's 13F filing for Q1 2017, filed 15 May 2017.